Potentially Resectable
1 clinical trials · Condition
◉ Watch Potentially Resectable
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer (NCT07323056) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-01-01 |
Track Potentially Resectable automatically
Every clearance here is in the API, with alerts when new ones post.